[Form 4] eHealth, Inc. Insider Trading Activity

Rhea-AI Filing Summary

NewAmsterdam Pharma Company N.V. (ticker NAMSW) has filed a Form 144 indicating that affiliate NAP PoolCo B.V. intends to sell up to 1,433,193 ordinary shares through UBS Financial Services on or after 14 July 2025. Based on the filing’s stated market value of $30.9 million, the proposed sale represents roughly 1.3 % of the company’s 112.3 million shares outstanding, potentially expanding the public float.

The notice also discloses that the same seller disposed of 303,197 shares on 16 June 2025 for gross proceeds of $5.9 million. No additional information regarding 10b5-1 plans, pricing discounts or company performance was provided. Form 144 is a standard regulatory requirement for affiliates; however, the magnitude of the sale could create short-term share-price pressure and may signal insider monetisation.

Positive

• Float expansion: Adding ~1.3 % of outstanding shares to the public float may enhance trading liquidity.

Negative

• Sizeable insider sale: Planned disposition of 1.43 M shares valued at $30.9 M could pressure the stock and signal lower insider confidence.
• Continued selling trend: Seller already disposed of 303,197 shares in June 2025, indicating ongoing liquidation.

Insights

Securities Analyst

TL;DR: Insider plans to sell 1.43 M NAMSW shares (~1.3 % O/S) worth $30.9 M; neutral-to-slightly negative sentiment.

The Form 144 filing signals a sizable insider liquidation by NAP PoolCo B.V. While Rule 144 sales are routine, the volume—over one percent of shares outstanding—can weigh on near-term supply/demand dynamics and be interpreted by some investors as reduced insider conviction. That said, the company’s free float will increase, potentially improving liquidity. The prior June sale shows an ongoing divestment pattern but is not large enough to materially impair control. Absent operating data, the filing’s impact hinges on market perception of insider selling rather than fundamentals.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Galimi Gavin G.

(Last) (First) (Middle)

C/O EHEALTH, INC.

13620 RANCH ROAD 620 N, SUITE A250

(Street)

AUSTIN TX 78717

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
eHealth, Inc. [ EHTH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, General Counsel & Secr.

3. Date of Earliest Transaction (Month/Day/Year)
07/10/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/10/2025		F(1)		839	D	$4.14	241,201	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the withholding of shares to satisfy tax withholding obligation.

Remarks:

	/s/ Sonwha Lee, as attorney-in-fact for Gavin G. Galimi	07/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many NAMSW shares are insiders planning to sell?

The filing covers up to 1,433,193 ordinary shares to be sold by NAP PoolCo B.V.

What is the market value of the proposed Form 144 sale?

The aggregate market value stated in the filing is approximately $30.9 million.

What percentage of NewAmsterdam Pharma’s shares outstanding does the sale represent?

It represents roughly 1.3 % of the 112,270,677 shares outstanding.

When are the NAMSW shares expected to be sold?

The approximate sale date listed is 14 July 2025.

Who is executing the transaction for the seller?

UBS Financial Services Inc. is the designated broker for the sale on Nasdaq.

Were any NAMSW shares sold recently by the same insider?

Yes, 303,197 shares were sold on 16 June 2025 for $5.9 million in gross proceeds.